Relay Therapeutics, Inc. Insider Trading Activity
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Insider Trade Summary
Grant/Award: 5,000 shares
Grant/Award
1 txn
Insider
Patel Sanjiv
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 5,000 | $2.94 | $15K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 826,667 shares (Direct);
Common Stock — 199,548 shares (Indirect, By The Patel Family Irrevocable Trust of 2019);
Common Stock — 687,355 shares (Indirect, By The SSP Irrevocable Trust of 2020)
Footnotes (4)
- F1. The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
- F2. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025.
- F3. Includes 410,560 shares underlying RSUs.
- F4. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
AI-generated analysis. How Rhea-AI works. Not financial advice.